渗透泵口服系统哌甲酯对年轻男性囚犯ADHD症状的随机对照试验
一项8周平行组双盲随机安慰剂对照试验在16-25岁符合DSM-5 ADHD诊断的男性囚犯中评估渗透泵口服系统哌甲酯(OROS-哌甲酯)的疗效。主要结局CAARS-O评分在OROS-哌甲酯组较安慰剂组估计降低0.57分(95%CI -2.41至3.56),无统计学显著性;应答率分别为48.3%与47.9%。结论认为ADHD症状未对OROS-哌甲酯产生应答,研究结果不支持在该人群中常规使用OROS-哌甲酯治疗。
要点
- 8周OROS-哌甲酯组CAARS-O评分较安慰剂组估计降低0.57分(95%CI -2.41至3.56),无统计学显著性。
- 应答率(CAARS-O评分降低20%)OROS-哌甲酯组48.3% vs 安慰剂组47.9%。
核心结论
- 在年轻成年男性囚犯中,ADHD症状未对OROS-哌甲酯产生应答,研究结果不支持在该人群中常规使用OROS-哌甲酯治疗。
研究设计与样本
- 8周平行组、双盲、随机安慰剂对照试验,对象为符合DSM-5 ADHD诊断标准的16-25岁男性囚犯,比较OROS-哌甲酯与安慰剂。
主要发现
- 8周时OROS-哌甲酯组CAARS-O评分较安慰剂组估计降低0.57分(95%CI -2.41至3.56),无统计学显著性。
- 应答率(CAARS-O评分降低20%)OROS-哌甲酯组48.3% vs 安慰剂组47.9%。
- OROS-哌甲酯组平均最终滴定剂量为53.8 mg。
关键数值与推荐
- 主要结局为8周时研究者评定的Connors成人ADHD评定量表(CAARS-O)ADHD症状。
- 应答定义为CAARS-O评分降低20%。
- OROS-哌甲酯组平均最终滴定剂量为53.8 mg。
临床怎么用
- 研究结果不支持在年轻成年男性囚犯中常规使用OROS-哌甲酯治疗ADHD。
- 原文指出需进一步研究评估更高平均剂量及治疗依从性、多模式治疗和社区预防性干预的效果。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Research has shown that 20-30% of prisoners meet the diagnostic criteria for attention-deficit hyperactivity disorder (ADHD). Methylphenidate reduces ADHD symptoms, but effects in prisoners are uncertain because of comorbid mental health and substance use disorders. AIMS: To estimate the efficacy of an osmotic-release oral system methylphenidate (OROS-methylphenidate) in reducing ADHD symptoms in young adult prisoners with ADHD. METHOD: We conducted an 8-week parallel-arm, double-blind, randomised placebo-controlled trial of OROS-methylphenidate versus placebo in male prisoners (aged 16-25 years) meeting the DSM-5 criteria for ADHD. Primary outcome was ADHD symptoms at 8 weeks, using the investigator-rated Connors Adult ADHD Rating Scale (CAARS-O). Thirteen secondary outcomes were measured, including emotional dysregulation, mind wandering, violent attitudes, mental health symptoms, and prison officer and educational staff ratings of behaviour and aggression. RESULTS: In the OROS-methylphenidate arm, mean CAARS-O score at 8 weeks was estimated to be reduced by 0.57 points relative to the placebo arm (95% CI -2.41 to 3.56), and non-significant. The responder rate, defined as a 20% reduction in CAARS-O score, was 48.3% for the OROS-methylphenidate arm and 47.9% for the placebo arm. No statistically significant trial arm differences were detected for any of the secondary outcomes. Mean final titrated dose was 53.8 mg in the OROS-methylphenidate arm. CONCLUSIONS: ADHD symptoms did not respond to OROS-methylphenidate in young adult prisoners. The findings do not support routine treatment with OROS-methylphenidate in this population. Further research is needed to evaluate effects of higher average dosing and adherence to treatment, multi-modal treatments and preventative interventions in the community.
引用
- Asherson PJ, Johansson L, Holland R, et al. Randomised controlled trial of the short-term effects of osmotic-release oral system methylphenidate on symptoms and behavioural outcomes in young male prisoners with attention deficit hyperactivity disorder: CIAO-II study. Br J Psychiatry. 2023. PMID: 35657651. doi:10.1192/bjp.2022.77
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。